{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:18:03Z","timestamp":1775110683179,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T therapy, is approved for relapsed\/refractory multiple myeloma (RRMM). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common, but reversible cerebral vasoconstriction syndrome (RCVS) is a previously unreported complication following cilta-cel. A 63-year-old female with RRMM (IgA lambda, t(14;16)), no vascular risk factors, received cilta-cel after two prior therapies, including autologous transplantation. On day +10 post-CAR-T infusion, she developed grade 1 CRS, managed with tocilizumab and vasopressors, including midodrine. On day +19, she presented with headache, leg weakness, and loss of fine motor skills. Neuroimaging showed multifocal cerebral stenosis and ischemic strokes, initially suggesting vasculitis. Subsequent imaging confirmed RCVS (RCVS2 score 9). Treatment with corticosteroids, anakinra, siltuximab, cyclophosphamide, verapamil, and nimodipine failed to halt neurological decline, resulting in right-sided hemiplegia and Gerstmann\u2019s and Balint\u2019s syndromes. By day +69, CT angiography showed resolved stenosis, but neurological deficits persisted. This case identifies RCVS as a novel, life-threatening complication following cilta-cel, possibly linked to CRS, tocilizumab, or midodrine. It underscores the need for broader differential diagnoses and tailored management for CAR-T neurotoxicities, warranting further research.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1783051","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:23:54Z","timestamp":1775107434000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Tuan L.","family":"Phan","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Hijazi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romi","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Ridha","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tirisham V.","family":"Gyang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Shujaat","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Ohio State University, Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid","family":"Nimjee","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Ohio State University, Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Slivka","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mhd Ezzat","family":"Zaghlouleh","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Jordan","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Blachly","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Brammer","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evandro","family":"Bezerra","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh","family":"Bumma","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Benson","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Umyarova","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Devarakonda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Cottini","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley E.","family":"Rosko","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (>\/=5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood marrow transplantation: J Am Soc For Blood Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.12.002","article-title":"Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data","volume":"31","author":"Ellithi","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/17474930231181250","article-title":"Reversible cerebral vasoconstriction syndrome: a review of pathogenesis, clinical presentation, and treatment","volume":"18","author":"Singhal","year":"2023","journal-title":"Int J Stroke"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy-a cohort study","volume":"13","author":"Korell","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012470","article-title":"Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma","volume":"8","author":"Mejia Saldarriaga","year":"2024","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1576","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"WIREs Mech Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Caldes","year":"2023","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/1756285609347123","article-title":"Diagnosis and treatment of cerebral vasculitis","volume":"3","author":"Berlit","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02679-y","article-title":"ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling","volume":"60","author":"Gomez-Llobell","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/head.13466","article-title":"Tocilizumab-associated reversible cerebral vasoconstriction: a case report","volume":"59","author":"Gonzalez-Martinez","year":"2019","journal-title":"Headache"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4285","article-title":"Reversible cerebral vasoconstriction syndrome due to midodrine in a patient with autonomic dysreflexia","volume":"11","author":"Shankar Kikkeri","year":"2019","journal-title":"Cureus"},{"key":"B18","article-title":"Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers","volume":"12","author":"Grobecker","year":"1993","journal-title":"Int Angiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jon.13138","article-title":"Neuroimaging of complications arising after CD19 chimeric antigen receptor T-cell therapy: a review","volume":"33","author":"Pinto","year":"2023","journal-title":"J Neuroimaging"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106472","article-title":"PRES and RCVS: two distinct entities or a spectrum of the same disease","volume":"31","author":"Jeanneret","year":"2022","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.122.038673","article-title":"Risk of stroke after posterior reversible encephalopathy syndrome","volume":"53","author":"Parauda","year":"2022","journal-title":"Stroke"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1783051\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:23:55Z","timestamp":1775107435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1783051\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1783051"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1783051","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"article-number":"1783051"}}